Novel insulins: expanding options in diabetes management.
about
Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.Intentional overdose with insulin glargine and insulin aspart.Inhaled insulin delivery--where are we now?Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine.Premixed insulin treatment for type 2 diabetes: analogue or human?Lispro insulin-induced lipoatrophy: a new case.Management of progressive type 2 diabetes: role of insulin therapy.Development of a clinical type 1 diabetes metabolic system model and in silico simulation toolIn silico simulation of long-term type 1 diabetes glycemic control treatment outcomes.Impact of Absorption and Transport on Intelligent Therapeutics and Nano-scale Delivery of Protein Therapeutic Agents.Basal insulin: physiology, pharmacology, and clinical implications.Why most oral insulin formulations do not reach clinical trials.Effect of insulin analogues on phosphatidyl inositol-3 kinase/Akt signalling in INS-1 rat pancreatic derived β-cells.Direct comparison of radioimmunoassay and LC-MS/MS for PK assessment of insulin glargine in clinical development.Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
P2860
Q28728738-461B5261-3FCC-4407-B0BF-68CC68EF55DBQ35671873-08668F78-B64D-4578-BE99-35ED3C406580Q35847886-EA60F619-6705-44D6-9CDD-6D430D5F9D6AQ35998015-60168919-7A45-46BB-AB6D-154BA6D94BFBQ36616573-22969578-6BD5-4A2F-AC4E-5A65C3701293Q36756637-2DE48A91-0065-4B4A-93C1-F5DE399429C1Q36909524-F153385F-BCCF-4B3F-BD2E-59CE0F64BD33Q37013116-2B7D8397-F489-4705-BC70-A61555835854Q37276717-295E79FA-3832-4C2B-A7AB-1A01FA3DDE5FQ37404167-29BB1745-941C-470C-AF0F-301F838E87FCQ37404176-828AE36B-0BAE-4087-824D-58D1D7E9821BQ37436438-AAE53352-8434-44F3-AC9F-4594EB2CAF3EQ37890774-F8069754-0565-4B15-AF29-0ABBF7C8AAE5Q38566437-A7AA333A-3709-4B8E-A712-CD7AFC87F6B5Q38808885-EEAF9A4B-CD60-4E05-8F61-F83EC69D6EEEQ41656524-6BCD146E-AAE9-4E09-B154-9D750BE5C934Q46758013-81622282-4E28-4282-990C-61B0E18D1CC6
P2860
Novel insulins: expanding options in diabetes management.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Novel insulins: expanding options in diabetes management.
@ast
Novel insulins: expanding options in diabetes management.
@en
Novel insulins: expanding options in diabetes management.
@nl
type
label
Novel insulins: expanding options in diabetes management.
@ast
Novel insulins: expanding options in diabetes management.
@en
Novel insulins: expanding options in diabetes management.
@nl
prefLabel
Novel insulins: expanding options in diabetes management.
@ast
Novel insulins: expanding options in diabetes management.
@en
Novel insulins: expanding options in diabetes management.
@nl
P1476
Novel insulins: expanding options in diabetes management.
@en
P2093
John E Gerich
P304
P356
10.1016/S0002-9343(02)01176-2
P407
P577
2002-09-01T00:00:00Z